First Patient Dosed in Phase 1 Trial of SY-5609 for OC, Other Solid Tumors, Syros Announces

First Patient Dosed in Phase 1 Trial of SY-5609 for OC, Other Solid Tumors, Syros Announces
Syros Pharmaceuticals announced the dosing of the first patient in its Phase 1 trial of SY-5609, an investigational oral medication for ovarian cancer and other types of solid tumors. The Phase 1 trial (NCT04247126) is a multi-center, open-label, dose-escalation study that plans to enroll approximately 60 people with advanced forms of ovarian, breast, colorectal, or lung cancer, or with solid tumors harboring alterations in the Rb pathway — a signaling cascade often inactivated in many types of cancers. Recruitment is underway at two clinical sites in the U.S., in Michigan and Texas. More information is available here. The study’s main goal is to assess the safety and tolerability of escalating doses of SY-5609 and establish a maximum tolerated dose. Additional study goals include assessing the compound's anti-tumor activity, pharmacokinetic and pharmacodynamic properties, and potential predictive
Subscribe or to access all post and page content.